152 related articles for article (PubMed ID: 15168599)
1. Thalidomide-induced severe neutropenia during treatment of multiple myeloma.
Hattori Y; Kakimoto T; Okamoto S; Sato N; Ikeda Y
Int J Hematol; 2004 Apr; 79(3):283-8. PubMed ID: 15168599
[TBL] [Abstract][Full Text] [Related]
2. Melphalan, prednisone, and lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results.
Palumbo A; Falco P; Falcone A; Benevolo G; Canepa L; Gay F; Larocca A; Magarotto V; Gozzetti A; Luraschi A; Morabito F; Nozza A; Knight RD; Zeldis JB; Boccadoro M; Petrucci MT
Clin Lymphoma Myeloma; 2009 Apr; 9(2):145-50. PubMed ID: 19406725
[TBL] [Abstract][Full Text] [Related]
3. Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
Sun HL; Atenafu EG; Yeboah E; Reece DE; Trudel S; Kukreti V; Masih-Khan E; Winter A; Chen C
Leuk Lymphoma; 2015 Feb; 56(2):407-14. PubMed ID: 24738975
[TBL] [Abstract][Full Text] [Related]
4. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide-associated thrombocytopenia.
Duyvendak M; Naunton M; Kingma BJ; Brouwers JR
Ann Pharmacother; 2005 Nov; 39(11):1936-9. PubMed ID: 16219892
[TBL] [Abstract][Full Text] [Related]
6. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome.
Kakimoto T; Hattori Y; Okamoto S; Sato N; Kamata T; Yamaguchi M; Morita K; Yamada T; Takayama N; Uchida H; Shimada N; Tanigawara Y; Ikeda Y
Jpn J Cancer Res; 2002 Sep; 93(9):1029-36. PubMed ID: 12359057
[TBL] [Abstract][Full Text] [Related]
11. Low-dose thalidomide-induced agranulocytosis in a multiple myeloma patient treated at diagnosis.
Mazzotta S; Gozzetti A; Pirrotta MT; Bocchia M; Sammassimo S; Bucalossi A; Lauria F
Leuk Lymphoma; 2005 Dec; 46(12):1837-8. PubMed ID: 16263590
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma.
Geng C; Hou J; Zhao Y; Ke X; Wang Z; Qiu L; Xi H; Wang F; Wei N; Liu Y; Yang S; Wei P; Zheng X; Huang Z; Zhu B; Chen WM
Am J Hematol; 2014 Nov; 89(11):1037-42. PubMed ID: 25092564
[TBL] [Abstract][Full Text] [Related]
13. [Single-agent thalidomide for advanced and refractory multiple myeloma].
Okikawa Y; Takimoto Y; Noda M; Imagawa J; Katayama Y; Sakai A; Okita H; Fujimura K; Kimura A
Rinsho Ketsueki; 2003 Jun; 44(6):368-74. PubMed ID: 12884814
[TBL] [Abstract][Full Text] [Related]
14. An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
Leleu X; Terpos E; Sanz RG; Cooney J; O'Gorman P; Minarik J; Greil R; Williams C; Gray D; Szabo Z
Am J Hematol; 2016 Aug; 91(8):806-11. PubMed ID: 27169523
[TBL] [Abstract][Full Text] [Related]
15. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program.
Steurer M; Spizzo G; Mitterer M; Gastl G
Onkologie; 2004 Apr; 27(2):150-4. PubMed ID: 15138347
[TBL] [Abstract][Full Text] [Related]
16. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
[TBL] [Abstract][Full Text] [Related]
17. The future role of thalidomide in multiple myeloma.
Boccadoro M; Blade J; Attal M; Palumbo A
Acta Haematol; 2005; 114 Suppl 1():18-22. PubMed ID: 16166768
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
19. [Retrospective analysis of thalidomide therapy in patients with relapsed/refractory multiple myeloma].
Ikebe T; Ogata M; Miyazaki M; Miyazaki Y; Ohtsuka E; Saburi Y; Goto K; Ikewaki J; Kohno K; Uno N; Imamura T; Akagi T; Kadota J
Rinsho Ketsueki; 2010 Feb; 51(2):114-21. PubMed ID: 20379102
[TBL] [Abstract][Full Text] [Related]
20. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
